Silverback Therapeutics (SBTX) aims to raise $125 million from the sale of its common stock in an IPO, according to an amended registration statement. Seattle, Washington-based Silverback was ...

Silverback Therapeutics, operating as ARS Pharmaceuticals, Inc., recently disclosed its unaudited financial results for the fourth quarter ended December 31, 2024, in a press release linked to a ...

Most recently CEO of Silverback Therapeutics, and president and CEO of Synthorx, Shawver brings to the table “more than 20 years of experience in executive leadership positions in oncology and ...

Dr. Blackman co-founded Day One Biopharmaceuticals in 2018 with a vision to identify, acquire, and develop promising new treatments to address childhood cancers. Under Dr. Blackman’s leadership, Day ...

Investing.com - ARS Pharmaceuticals (NASDAQ: SPRY) reported first quarter EPS of $-0.16, $0.03 worse than the analyst estimate of $-0.13. Revenue for the quarter came in at $20K... ByInvesting.com ...

Investing.com – U.S. stocks were mixed after the close on Thursday, as gains in the Consumer Services, Telecoms and Technology sectors led shares higher while losses in the Basic ...